Risk of neutropenia prompts new monitoring for antipsychotic drug
September 18, 2015
FDA announced new requirements for the monitoring, prescribing, and dispensing of clozapine, an atypical antipsychotic for treatment-resistant schizophrenia, due to the continued risk of severe neutropenia, which can be life-threatening.